$CDNA

Hanna John Walter JR sold $1.2M of CDNA

Hanna John Walter JR (President and CEO) sold 40,000 shares of CareDx, Inc. (CDNA) at an average of $29.24 ($29.00–$29.24, $1.17M total) across 2 trades over 2026-06-26 to 2026-06-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Hanna John Walter JR
Published Jun 30, 2026, 9:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 30, 2026, 9:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CDNA
Neutral
medium confidence
Mentioned
$CDNA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CDNANeutralLow
01

Why it matters

The newest information is the specific sale size, price range, and that it occurred under a pre-arranged 10b5-1 plan; this typically has limited fundamental impact but can influence short-term sentiment.

02

Market read

Traders may monitor for follow-on insider activity, but the disclosure alone does not change the company’s fundamentals.

03

What to watch

The article does not disclose any concurrent changes in guidance, contracts, or clinical/operational milestones—so the trading signal should be treated as sentiment-only.

Relevance 5/10Novelty 5/10Timing: after-hours/filing date (2026-06-30) for the latest insider-sale disclosure

Background

The article is an SEC Form 4 insider transaction disclosure for CareDx, Inc. (CDNA) by its President and CEO, Hanna John Walter Jr.

Company-level read

Ticker impact

$CDNANeutralMedium confidence
Context

CareDx CEO sold about 40,000 shares in open-market transactions at ~$29.00–$29.24, per a newly filed SEC Form 4.

Expected impact

Likely limited, short-lived sentiment impact unless follow-on selling or other disclosures emerge.

Evidence & confidence

The filing is a routine Form 4 open-market sale under a pre-arranged 10b5-1 plan; it provides timing/size but no new operating or financial information.

Market effects

Minimal; this is company-specific insider activity with no sector-wide catalyst described.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect diversification/liquidity needs rather than bearish expectations.

Key entities

  • CareDx, Inc.

    Issuer of the Form 4 insider transaction; CEO sold shares in open-market trades.

  • Hanna John Walter Jr

    President and CEO who executed the reported open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CDNAMed

CareDx (CDNA) Stock Jumps 13.0%: Will It Continue to Soar?

CareDx (CDNA) shares rose 13% to $61.37 on high volume, following a price target increase to $74 by BTIG. Q2 2026 revenue grew 52% YoY, with testing services up 61%. Q3 earnings are expected at $0.24 per share, down 14.3% YoY, and revenue at $122.35M, up 22.3% YoY. The stock has a Zacks Rank of #2 (Buy). Charles River Laboratories (CRL), another medical services company, closed up 6.2% at $294.44, with a Zacks Rank of #2 (Buy).